Screener
Acadia Pharmaceuticals ACAD Income Tax
Income Tax at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Acadia Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333243
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Interest income, net | 7,990 | 7,243 | 16,045 | 15,144 |
| Other income | 647 | 594 | 1,189 | 1,183 |
| Income before income taxes | 46,473 | 40,211 | 50,454 | 67,990 |
| Income tax expense | 14,973 | 13,545 | 15,317 | 22,337 |
| Net income | $31,500 | $26,666 | $35,137 | $45,653 |
| Earnings per share: | ||||
| Basic | $0.18 | $0.16 | $0.21 | $0.27 |
| Diluted | $0.18 | $0.16 | $0.20 | $0.27 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Acadia Pharmaceuticals's income tax?
- Acadia Pharmaceuticals (ACAD) reported income tax of $14.97M in Q2 2026.
- How has Acadia Pharmaceuticals's income tax changed year-over-year?
- Acadia Pharmaceuticals's income tax increased by 10.5% year-over-year, from $13.55M to $14.97M.
- What is the long-term trend for Acadia Pharmaceuticals's income tax?
- Over 3 years (2021 to 2025), Acadia Pharmaceuticals's income tax has grown at a 795.5% compound annual growth rate (CAGR), from $351K to -$252.1M.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.
Ask your AI about Acadia Pharmaceuticals's income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude